Chiron Corporation, maker of interleukin-2 (IL-2), the most promising immunotherapy for HIV, for dropping the most important study of the drug without completing it. The company has given various excuses and reasons, but the bottom line is money and an intention to become less involved in HIV. Negotiations are underway to revive a streamlined version of the study, but Chiron continues to offer less financial support than needed.
Want to tell them how you feel about this? Write or email:
Sean P. Lance, CEO
4560 Horton Street
Emeryville, CA 94608-2916
Back to the Project Inform Perspective January 2003 contents page.